Using MRI and Genomic Testing to Guide Prostate Cancer Treatment Choices
Expanding an Active Surveillance Cohort to Improve Survivorship for Men With Favorable Risk Prostate Cancer
This study is testing whether using MRI and genetic tests can help doctors better choose treatment for prostate cancer in men, especially focusing on Black men and those from lower-income backgrounds.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 222 (estimated) |
| Ages | 40 Years to 76 Years |
| Sex | Male |
| Sponsor | Northwestern University Academic / other |
| Locations | 2 sites (Chicago, Illinois and 1 other locations) |
| Trial ID | NCT05424783 on ClinicalTrials.gov |
What this trial studies
This study aims to recruit men considering active surveillance for prostate cancer treatment, particularly focusing on Black men and those from lower socioeconomic backgrounds. It evaluates the effectiveness of multi-parametric magnetic resonance imaging (mpMRI) and Genomic Prostate Score (GPS) assays in identifying men at risk for aggressive disease. By improving patient selection and adherence to monitoring, the study seeks to enhance the safety and acceptability of active surveillance as a treatment option. The research is conducted at safety net hospitals to address disparities in prostate cancer management.
Who should consider this trial
Good fit: Ideal candidates are men aged 40-76 with very low to favorable intermediate risk prostate cancer who are considering active surveillance.
Not a fit: Patients with a life expectancy of less than 10 years or those unable to undergo MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better treatment decisions and reduced overtreatment for men with prostate cancer.
How similar studies have performed: Previous studies have shown promise in using GPS and mpMRI for risk stratification in prostate cancer, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participants must have NCCN very low to favorable intermediate risk prostate cancer. * Participants must be diagnosed within 3 months prior to study enrollment. * Participants must be male, age 40-76 years old. * Participants must be willing to consider active surveillance for treatment. Exclusion Criteria: * Participants with less than 10 years life expectancy. * Participants unable to complete standardized surveys. * Participants with no access to the rectum for a transrectal ultrasound. * Participants with a contraindication to magnetic resonance imaging (MRI).
Where this trial is running
Chicago, Illinois and 1 other locations
- Northwestern University — Chicago, Illinois, United States (Active_not_recruiting)
- University of Illinois at Chicago — Chicago, Illinois, United States (Recruiting)
Study contacts
- Study coordinator: Adam B Murphy, MD,MBA,MSCI
- Email: a-murphy2@northwestern.edu
- Phone: 312-908-2002
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.